Growth in the human augmentation sector won't happen equally. Whoever redefines this market will capture the lion's share of the $1.8 billion in profits up for grabs.
- Ekso Bionics: Now the First and Only FDA-Approved Exoskeleton
- How to Make 69% Off the Biotech Stock Rebound
- Why Biotech Stocks Will Outperform in 2016 – and Our Top Pick
- Ekso Stock – Better to Be Early Than Bail Because You're Impatient
- As Another Sector's Sails Lose Wind, Watch This One Barometer
- A Biotech Stock to Buy with "Nearly Limitless" Profit Potential
- How This Biotech Stock Gained Over 3,000% and Trapped Investors
- How to Pick the Best Biotech Stocks to Buy in Five Easy Steps
- One of the Top Biotech Stocks to Buy Just Hit the Market
- [Chart] Pharma Companies Make Billions as Prescription Spending Soars
- Why Trillium (Nasdaq: TRIL) Stock Is Today's Top Biotech Buy
- The Next Great Blockbuster Biotech Stock to Buy Now
- Top Biotechnology Companies Profiting from ASCO 2015
- How You Made 53% in Two Months with This Biotech Stock
- This Top Biotech Stock Just Got a $100 Billion "Buy" Signal
- Biotech Investing for Beginners: Your 7-Step Guide
Despite the recent slump, the life sciences sector - which includes biotech - offers investors some of the best long-term opportunities for building wealth.
And that means you definitely want biotech stocks in your portfolio, especially now.
Biotech stocks have stalled in 2016 along with the broader markets, with the iShares Nasdaq Biotech ETF (Nasdaq: IBB) down 24.43% year to date.
Still, Money Morning Biotech Investing Specialist Ernie Tremblay says the sector will outperform in 2016. And he's pinpointed one foundational play that's already climbed 14% in the last five days.
As you might expect, my email's been flooded with all kinds of questions, comments, and observations since the markets began their 7% slide downward in earnest.
Most are pretty straightforward - oil, the sell-off, China, Social Security, and more - but a number of them deal with our favorite Human Augmentation recommendation, Ekso Bionics.
One, in particular, was exceptionally blunt: Have we backed the wrong horse?
One by one, the bubbles are bursting...
First it was the commodities bubble that blew up in mid-2014, which caused the collapse of energy and commodity stocks -they are now down between 40-80%.
It also caused the end of the corporate credit bubble in high yield bonds and bank loans over the second half of 2014 and into this year.
Today, we're recommending a biotech stock to buy that Money Morning Biotech Investing Specialist Ernie Tremblay says has a "nearly limitless" profit potential.
It's a medical device company with a revolutionary product that helps restore vision to people suffering from blindness.
For biotech stock investors, what happened to Aquanox Pharmaceuticals Inc. (Nasdaq: AQXP) over the past week looked like the ultimate fantasy come true.
After reporting positive results from a mid-stage test for its bladder pain syndrome/interstitial cystitis drug AQX-1125 on Aug. 7, Aquanox stock took off like a rocket. At one point it was up more than 3,000%.
Investors who know how to choose the best biotech stocks to buy can cash in. In the last twelve months alone, the Nasdaq Biotechnology Index ETF has outperformed the broader Nasdaq Composite by 25.5%. And the SPDR S&P Biotech ETF has outperformed the S&P 500 almost sevenfold.
One of the last week's biggest IPOs, the food allergy company Aimmune Therapeutics Inc. (Nasdaq: AIMT), hit the market on Thursday, Aug. 6, and has already climbed more than 20%.
AIMT's early success underscores one of the best biotech stocks to buy that Money Morning Executive Editor Bill Patalon has been recommending all year.
Prescription drug spending continues to hit record highs, and the world's top pharma companies continue to bank billions.
More than $374 billion was spent on prescription drugs in the United States in 2014, according to a report from the IMS Institute of Health. That was a 13.1% jump from 2013, and the highest growth rate in more than a decade, says ExpressScripts.
Trillium Therapeutics Inc. (Nasdaq: TRIL) stock has climbed 143% in 2015, and it's still one of the top biotech stocks to buy now.
You see, Trillium is at the forefront of a revolutionary treatment that could hold the key to curing various types of cancer.
Spending on cancer treatment has been skyrocketing globally. According to the IMS Institute of Health, spending on cancer topped $100 billion globally in 2014. That was a 10% increase from 2013.
That's why many biotech stocks tied to cancer treatments have seen triple-digit gains in the last two years.
The American Society of Clinical Oncology (ASCO) held its annual meeting in Chicago this week.
More than 30,000 people attend the event, which features more than 4,000 presentations from some of the top biotechnology companies in the world.
We first recommended this incredible biotech stock in 2013. It's since realized a growth of 342%.
And better yet: it's expected to continue growing at an exponential rate.
Global cancer spending topped $100 billion for the first time after climbing a whopping 10% in 2014.
And that's a major "buy" signal for one of the top biotech stock picks we've been recommending at Money Morning.
According to a report from the IMS Institute of Health, rising drug prices and increased incidence of cancer led to the 10% spike in drug spending last year.